For patients with highly aggressive FLT3-ITD positive AML, a combination of FLT3- and MDM2-inhibitor may be a justified first line therapy, which could be followed by a second line therapy with a combination of MCL1- and MEK-inhibitor. The gene discussed is FLT3; the disease is acute myeloid leukemia.